Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy
Deborah Pencharz, Gopinath Gnanasegaran, Shaunak Navalkissoor
British Journal of Radiology (2018) Vol. 91, Iss. 1091, pp. 20180108-20180108
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Current Advances in PARP1‐Targeted Theranostics
Jie Tong, Baosheng Chen, Tommaso Volpi, et al.
Journal of Labelled Compounds and Radiopharmaceuticals (2025) Vol. 68, Iss. 1-2
Closed Access | Times Cited: 1
Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
Lilja B. Sólnes, Rudolf A. Werner, Krystyna M. Jones, et al.
Journal of Nuclear Medicine (2020) Vol. 61, Iss. 3, pp. 311-318
Open Access | Times Cited: 55
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors
Silvia Nicolini, Lisa Bodei, Alberto Bongiovanni, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 10, pp. 3260-3267
Open Access | Times Cited: 47
Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
Cristina Barca, Christoph M. Griessinger, Andreas Faust, et al.
Pharmaceuticals (2021) Vol. 15, Iss. 1, pp. 13-13
Open Access | Times Cited: 42
Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression
Andrey A. Rosenkranz, Tatiana A. Slastnikova, Т. А. Кармакова, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 45
The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
Virginia Liberini, Martin W. Huellner, Séréna Grimaldi, et al.
Diagnostics (2020) Vol. 10, Iss. 12, pp. 1083-1083
Open Access | Times Cited: 37
Synthesis of 68Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced 68Ga as exemplified by [68Ga]Ga-PSMA-11 for prostate cancer PET imaging
Melissa E. Rodnick, Carina Sollert, Daniela Stark, et al.
Nature Protocols (2022) Vol. 17, Iss. 4, pp. 980-1003
Closed Access | Times Cited: 22
Immunohistochemical Expression of Somatostatin Receptor Subtypes in a Panel of Neuroendocrine Neoplasias
Satu Maria Remes, Helena Leijon, Tiina Vesterinen, et al.
Journal of Histochemistry & Cytochemistry (2019) Vol. 67, Iss. 10, pp. 735-743
Open Access | Times Cited: 33
Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide
Solmaz AghaAmiri, Sukhen C. Ghosh, Servando Hernandez Vargas, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2425-2437
Closed Access | Times Cited: 3
An Impressive Approach in Nuclear Medicine
Nasim Vahidfar, Elisabeth Eppard, Saeed Farzanehfar, et al.
PET Clinics (2021) Vol. 16, Iss. 3, pp. 327-340
Closed Access | Times Cited: 19
Actinium-225 Targeted Agents: Where Are We Now?
Firas Mourtada, Katsumi Tomiyoshi, Jennifer Sims‐Mourtada, et al.
Brachytherapy (2023) Vol. 22, Iss. 6, pp. 697-708
Open Access | Times Cited: 8
(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer
Irina Velikyan
Pharmaceuticals (2020) Vol. 13, Iss. 3, pp. 39-39
Open Access | Times Cited: 15
The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.
Virginia Liberini, Martin Hüllner, Séréna Grimaldi, et al.
(2020)
Open Access | Times Cited: 11
Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects
Aayushi C. Shah, Akshada S. Dabhade, Hetvi Bharadia, et al.
Zeitschrift für Naturforschung C (2024) Vol. 79, Iss. 9-10, pp. 235-266
Closed Access | Times Cited: 1
Preparation of [68Ga]GaCl3 Using a Cyclotron
Melissa E. Rodnick, Carina Sollert, D. Christian Parr, et al.
Methods in molecular biology (2023), pp. 55-64
Closed Access | Times Cited: 3
Side effects of theragnostic agents currently employed in clinical practice
Alessio Rizzo, Salvatore Annunziata, Massimo Salvatori
The Quarterly Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 65, Iss. 4
Closed Access | Times Cited: 7
Optimisation of radioligand therapy in neuroendocrine tumours: Current and evolving evidence
Shaunak Navalkissoor, Gopinath Gnanasegaran, Ashley Grossman
Journal of Neuroendocrinology (2022) Vol. 34, Iss. 11
Closed Access | Times Cited: 5
Prevalence of incidental thyroid malignancy on routine 18F-fluorodeoxyglucose PET-CT in a large teaching hospital
Shea Roddy, Thomas Biggans, A. K. raofi, et al.
European Journal of Hybrid Imaging (2020) Vol. 4, Iss. 1
Open Access | Times Cited: 6
New Isotopes for the Treatment of Pancreatic Cancer in Collaboration With CERN: A Mini Review
Claudia Burkhardt, L. Bühler, David Viertl, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 6
Focal Liver Uptake on FDG PET/CT Without CT Correlate: Utility of MRI in the Evaluation of Patients With Known Malignancy
Tetsuro Araki, Tarek H. Mouhieddine, Sree Harsha Tirumani, et al.
American Journal of Roentgenology (2019) Vol. 213, Iss. 1, pp. 175-181
Closed Access | Times Cited: 4
Clinicopathologic features and BRAF mutation status of tracheal glomus tumors - Characterization of 4 cases and the distinction from low-grade neuroendocrine tumors
Jie Lin, Jie Luo, Huang Chen, et al.
Annals of Diagnostic Pathology (2021) Vol. 55, pp. 151797-151797
Closed Access | Times Cited: 4
Hepatobiliary Imaging
Janet H. Pollard
(2023), pp. 456-484
Closed Access | Times Cited: 1
Applications of radiolabeled antibodies in neuroscience and neuro‐oncology
Ryan J. Pakula, Peter J. H. Scott
Journal of Labelled Compounds and Radiopharmaceuticals (2023) Vol. 66, Iss. 9, pp. 269-285
Open Access | Times Cited: 1
Assessment of DNA/RNA Deregulation in Cancer Using 99mTc-Labeled Thiopurine
Chuang‐Hsin Chiu, David J. Yang, Yi-Chen Liou, et al.
Cancer Biotherapy and Radiopharmaceuticals (2024) Vol. 39, Iss. 5, pp. 358-372
Open Access
Invited Commentary: Application of Hybrid Somatostatin Receptor PET/MRI of the Head and Neck
Deborah R. Shatzkes, Sara Strauß
Radiographics (2024) Vol. 44, Iss. 10
Closed Access
Page 1 - Next Page

Scroll to top